D W Kaufman1, S Reshef2, H L Golub3, M Peucker4, M J Corwin5, D S Goodin6, V Knappertz7, D Pleimes2, G Cutter8. 1. Slone Epidemiology Center at Boston University, 1010 Commonwealth Avenue, Boston, MA 02215, USA. Electronic address: dwk@bu.edu. 2. Bayer HealthCare Pharmaceuticals, Montville, NJ, USA. 3. Care-Safe LLC, Waltham, MA, USA; Harvard-M.I.T. Division of Health, Sciences and Technology, Cambridge, MA, USA. 4. Care-Safe LLC, Waltham, MA, USA. 5. Slone Epidemiology Center at Boston University, 1010 Commonwealth Avenue, Boston, MA 02215, USA; Care-Safe LLC, Waltham, MA, USA. 6. Department of Neurology, University of California, San Francisco, CA, USA. 7. Bayer HealthCare Pharmaceuticals, Montville, NJ, USA; Department of Neurology, Heinrich Heine University, Düsseldorf, Germany; Teva Pharmaceuticals, R&D CNS, Frazer, PA, USA. 8. University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA.
Abstract
OBJECTIVE: Compare survival in patients with multiple sclerosis (MS) from a U.S. commercial health insurance database with a matched cohort of non-MS subjects. METHODS: 30,402 MS patients and 89,818 non-MS subjects (comparators) in the OptumInsight Research (OIR) database from 1996 to 2009 were included. An MS diagnosis required at least 3 consecutive months of database reporting, with two or more ICD-9 codes of 340 at least 30 days apart, or the combination of 1 ICD-9-340 code and at least 1 MS disease-modifying treatment (DMT) code. Comparators required the absence of ICD-9-340 and DMT codes throughout database reporting. Up to three comparators were matched to each patient for: age in the year of the first relevant code (index year - at least 3 months of reporting in that year were required); sex; region of residence in the index year. Deaths were ascertained from the National Death Index and the Social Security Administration Death Master File. Subjects not identified as deceased were assumed to be alive through the end of 2009. RESULTS: Annual mortality rates were 899/100,000 among MS patients and 446/100,000 among comparators. Standardized mortality ratios compared to the U.S. population were 1.70 and 0.80, respectively. Kaplan-Meier analysis yielded a median survival from birth that was 6 years lower among MS patients than among comparators. CONCLUSIONS: The results show, for the first time in a U.S. population, a survival disadvantage for contemporary MS patients compared to non-MS subjects from the same healthcare system. The 6-year decrement in lifespan parallels a recent report from British Columbia.
OBJECTIVE: Compare survival in patients with multiple sclerosis (MS) from a U.S. commercial health insurance database with a matched cohort of non-MS subjects. METHODS: 30,402 MS patients and 89,818 non-MS subjects (comparators) in the OptumInsight Research (OIR) database from 1996 to 2009 were included. An MS diagnosis required at least 3 consecutive months of database reporting, with two or more ICD-9 codes of 340 at least 30 days apart, or the combination of 1 ICD-9-340 code and at least 1 MS disease-modifying treatment (DMT) code. Comparators required the absence of ICD-9-340 and DMT codes throughout database reporting. Up to three comparators were matched to each patient for: age in the year of the first relevant code (index year - at least 3 months of reporting in that year were required); sex; region of residence in the index year. Deaths were ascertained from the National Death Index and the Social Security Administration Death Master File. Subjects not identified as deceased were assumed to be alive through the end of 2009. RESULTS: Annual mortality rates were 899/100,000 among MS patients and 446/100,000 among comparators. Standardized mortality ratios compared to the U.S. population were 1.70 and 0.80, respectively. Kaplan-Meier analysis yielded a median survival from birth that was 6 years lower among MS patients than among comparators. CONCLUSIONS: The results show, for the first time in a U.S. population, a survival disadvantage for contemporary MS patients compared to non-MS subjects from the same healthcare system. The 6-year decrement in lifespan parallels a recent report from British Columbia.
Authors: Jay K Nathan; Amanda L Brezzell; Michelle M Kim; Denise Leung; D Andrew Wilkinson; Shawn L Hervey-Jumper Journal: J Neurooncol Date: 2017-07-25 Impact factor: 4.130
Authors: Deborah M Miller; Stacey S Cofield; Sarah M Planchon; Sarah E Givens; Amber Salter; Hollie K Schmidt; Sabrina Corlette; Carol C Musil Journal: Int J MS Care Date: 2021-08-18
Authors: Caila B Vaughn; Dejan Jakimovski; Katelyn S Kavak; Murali Ramanathan; Ralph H B Benedict; Robert Zivadinov; Bianca Weinstock-Guttman Journal: Nat Rev Neurol Date: 2019-06 Impact factor: 42.937
Authors: Emmanuelle Leray; Sandra Vukusic; Marc Debouverie; Michel Clanet; Bruno Brochet; Jérôme de Sèze; Hélène Zéphir; Gilles Defer; Christine Lebrun-Frenay; Thibault Moreau; Pierre Clavelou; Jean Pelletier; Eric Berger; Philippe Cabre; Jean-Philippe Camdessanché; Shoshannah Kalson-Ray; Christian Confavreux; Gilles Edan Journal: PLoS One Date: 2015-07-06 Impact factor: 3.240
Authors: Douglas S Goodin; Michael Corwin; David Kaufman; Howard Golub; Shoshana Reshef; Mark J Rametta; Volker Knappertz; Gary Cutter; Dirk Pleimes Journal: PLoS One Date: 2014-08-21 Impact factor: 3.240